KFU. Card publication. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection.

- RUS
- 中文
- ES

CILOSTAZOL AMELIORATES LIVER FIBROSIS IN A MASLD ANIMAL MODEL; POTENTIAL INVOLVEMENT OF LIVER SINUSOIDAL ENDOTHELIAL CELL PROTECTION.

Form of presentation

Conference proceedings in international journals and collections

Year of publication

2026

Authors, employees of KFU

Arslanova Alisa Nailevna, author

Khusnullina Alina Rinatovna, author

Other authors

Khisanori Goto, Kumi Kimura, Yasukhiko Yamamoto, Toshinari Takamura

Authors, postgraduates KFU

Arslanova Alisa Nailevna, postgraduate kfu

Khusnullina Alina Rinatovna, postgraduate kfu

Bibliographic description in the original language

A. Arslanova; A. Khusnullina; H. Goto; K. Kimura; Y. Yamamoto; T. Takamura. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection. MASLDモデルにおけるシロスタゾールの肝線維化改善と肝類洞内皮細胞保護の可能性. Abstracts. 39th Annual Scientific Meeting of the Japanese Society for Diabetes and Obesity in Animals. p.79 (82)

Annotation

Metabolic dysfunction-associated steatotic liver disease (MASLD) ? and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH) ? leads to injury of liver sinusoidal endothelial cells (LSECs) as a key driver of disease progression. The integrity of LSECs is essential for hepatic microvascular homeostasis, and their dysfunction may exacerbate parenchymal injury and fibrogenesis. Cilostazol, a phosphodiesterase-3 inhibitor, has demonstrated endothelial protective effects, enhancing endothelial function, reducing apoptosis, and modulating vasoactive mediators such as nitric oxide. However, it remains unknown whether cilostazol can similarly protect LSECs and thereby attenuate hepatic fibrosis in MASLD/MASH. We therefore investigated whether cilostazol mitigates liver fibrosis in a murine MASLD model complicated by diabetes, with a particular focus on the preservation of LSEC integrity. Mice were induced to develop MASH plus diabetes by combined feeding of a high-fat d

Keywords

MASLD, MASH, liver fibrosis, type 2 diabetes, cilostazol

Place of publication

��

Please use this ID to quote from or refer to the card

https://repository.kpfu.ru/eng/?p_id=324338&p_lang=2

Full metadata record

Field DC	Value	Language
dc.contributor.author	Arslanova Alisa Nailevna	ru_RU
dc.contributor.author	Khusnullina Alina Rinatovna	ru_RU
dc.contributor.author	Arslanova Alisa Nailevna	ru_RU
dc.contributor.author	Khusnullina Alina Rinatovna	ru_RU
dc.date.accessioned	2026-01-01T00:00:00Z	ru_RU
dc.date.available	2026-01-01T00:00:00Z	ru_RU
dc.date.issued	2026	ru_RU
dc.identifier.citation	A. Arslanova; A. Khusnullina; H. Goto; K. Kimura; Y. Yamamoto; T. Takamura. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection. MASLDモデルにおけるシロスタゾールの肝線維化改善と肝類洞内皮細胞保護の可能性. Abstracts. 39th Annual Scientific Meeting of the Japanese Society for Diabetes and Obesity in Animals. p.79 (82)	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/eng/?p_id=324338&p_lang=2	ru_RU
dc.description.abstract	Metabolic dysfunction-associated steatotic liver disease (MASLD) ? and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH) ? leads to injury of liver sinusoidal endothelial cells (LSECs) as a key driver of disease progression. The integrity of LSECs is essential for hepatic microvascular homeostasis, and their dysfunction may exacerbate parenchymal injury and fibrogenesis. Cilostazol, a phosphodiesterase-3 inhibitor, has demonstrated endothelial protective effects, enhancing endothelial function, reducing apoptosis, and modulating vasoactive mediators such as nitric oxide. However, it remains unknown whether cilostazol can similarly protect LSECs and thereby attenuate hepatic fibrosis in MASLD/MASH. We therefore investigated whether cilostazol mitigates liver fibrosis in a murine MASLD model complicated by diabetes, with a particular focus on the preservation of LSEC integrity. Mice were induced to develop MASH plus diabetes by combined feeding of a high-fat d	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	MASLD	ru_RU
dc.subject	MASH	ru_RU
dc.subject	liver fibrosis	ru_RU
dc.subject	type 2 diabetes	ru_RU
dc.subject	cilostazol	ru_RU
dc.title	Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection.	ru_RU
dc.type	Conference proceedings in international journals and collections	ru_RU